SLDB, US83422E2046

Solid Biosciences stock advances SGT-212 regulatory path

Published on 10/31/2026 at 01:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Solid Biosciences stock remains in focus after an EU orphan designation for SGT-212. The company also reported progress in its FALCON trial.

Solid advances SGT-212 development

The European Commission granted orphan designation to Solid Biosciences' SGT-212 for Friedreich's ataxia.
Five participants had received SGT-212 in the Phase 1b FALCON trial by October 5, with initial data expected in the first quarter of 2027.
Solid is developing gene therapies for rare neuromuscular and cardiac diseases.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences said on October 26, 2026, that the European Commission granted orphan designation to SGT-212 for the treatment of Friedreich's ataxia. The company also reported that five participants had received the investigational therapy in the Phase 1b FALCON trial, with no treatment-related serious adverse events observed as of October 5. The announcement was published by Solid Biosciences.

Regulatory status supports development

SGT-212 is designed as a dual-route gene therapy. Its development combines MRI-guided delivery to the cerebellar dentate nuclei with intravenous delivery intended to reach the heart and other systemic tissues affected by Friedreich's ataxia.

Solid said it expects to report initial FALCON clinical data in the first quarter of 2027. The program has also received Fast Track, Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration. These designations support the regulatory development path but do not establish the therapy's safety or effectiveness.

Pipeline spans rare diseases

Solid Biosciences develops precision genetic medicines for rare neuromuscular and cardiac diseases. Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy. The company is also developing genetic regulators and technologies intended to improve gene therapy delivery.